Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Plants of Epilobium angustifolium are popular in China to treatment of traumatic injury, subduing inflammation and menstrual disorders. In European, the preparations or extracts containing E. angustifolium are popular to treat prostate diseases. Recent research suggested that E. angustifolium showed therapeutic effects in early stage of BPH, inflammation of urethra and prostate, as well as micturition problems. And the related researches were focus on aqueous extract and its main constituent of oenothein B.AIM OF THE STUDY: This study aims to evaluate the therapeutic effect against BPH of the ethyl acetate extracts (EAE) and n-butanol extracts (BUE) from E. angustifolium and to chemical investigation of the active constituents.MATERIALS AND METHODS: The in vitro anti-BPH activity was assessed by determining the benign prostatic hyperplasia epithelial-1 (BPH-1) cell viability using MTT assay as well as suppressing of prostate specific antigen (PSA) secretion in prostate epithelial cancer hormone-dependent (LNCaP) cells measured by ELISA method. The in vivo anti-BPH was evaluated by testosterone propionate induced BPH SD rats. After oral administration of BUE at 100, 200 and 400 mg/kg B.W. for 28 days, the prostate weight and index, plasma androgen level, histopathological alteration, oxidative and inflammatory-related factors in prostate were assessed. Phytochemical investigation on active extracts was carried by chromatographic and spectroscopic techniques. Anti-BPH activities of the isolates were evaluated in vitro.RESULTS: BUE and EAE from E. angustifolium exhibited significant anti-BPH effect in vitro. Further in vivo study demonstrated that BUE exhibited therapeutic effects against TP-induced BPH in SD rats via down-regulating of the androgen level, suppressing the expression of NF-κB and eventually alleviating the inflammatory responses and oxidative stress. Phytochemical research on BUE and EAE extracts led to the isolation and identification of 50 compounds. In vitro anti-BPH screening revealed that 26 compounds exhibited anti-proliferation in BHP-1 cell and 36 compounds showed PSA inhibition in LNCap cell, in which 7 compounds exhibited very significant anti-BPH activities in both two cell lines (P < 0.01), 5 compounds with extremely significant activities in one of the cell lines (P < 0.001), and compound 25 exhibited the most potent anti-BPH activity (P < 0.001).CONCLUSIONS: E. angustifolium exhibited the therapeutic potential against BPH, and its active compounds may be used as candidate for treatment of BPH.

Study on Pollen and Its Extracts for the Treatment of Benign Prostatic Hyperplasia

Study on New Food Resource "masson Pine Pollen" on Provention of Prostatic Hypertrophy

Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia

Research Progress on Pathogenesis of Benign Prostatic Hyperplasia

Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia

The progress in genetics of Benign prostatic hyperplasia

Isolation and Identification of Active Compounds on Benign Prostate Hyperplasia from Oiltea camellia Extract

Study of cronical prostatitis and benigh prostatic hyperplasia

[PHYTOTHERAPY AND NATURAL AGENTS IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)]

Animal models of benign prostatic hyperplasia

Fermented rape pollen powder can alleviate benign prostatic hyperplasia in rats by reducing hormone content and changing gut microbiota.

Evidence-based Treatment in Patients Newly Diagnosed with Benign Prostatic Hyperplasia

Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.

Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview

The Effectiveness and Safety of Moxibustion for Treating Benign Prostatic Hyperplasia

Research progress of dutasteride in men with benign prostatic hyperplasia

[Progress in the Studies of Alpha1-Receptor Blocker for Benign Prostatic Hyperplasia].

Study on Mechanism of Zishen Pill treating Benign Prostatic Hyperplasia Based on Serum Pharmacochemistry and Network Pharmacology

Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia

What do we know about phytotherapy of benign prostatic hyperplasia?